Drugs /

pvx-410

Back to Drugs List

Overview

NCI Definition [1]:
A cancer vaccine containing immunogenic, HLA-A2-specific epitopes derived from X-box-binding protein 1-unspliced (XBP1-US), XBP1-spliced (SP), syndecan-1 (CD138), and CS1 (CD2 subset 1, CRACC, SLAMF7, CD319) with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, XBP1-US/XBP1-SP/CD138/CS1 multipeptide vaccine PVX-410 may stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens. The tumor associated antigens (TAAs) XBP1-US, XBP1-SP, CD138 and CS1, are overexpressed on the surface of multiple myeloma (MM) cells.

Clinical Trials

View Clinical Trials for pvx-410

Pvx-410 has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating pvx-410, 3 are phase 1 (3 open).

HLA-A*02 Positive, ER Negative, and ER No Expression are the most frequent biomarker inclusion criteria for pvx-410 clinical trials.

Breast carcinoma and smoldering plasma cell myeloma are the most common diseases being investigated in pvx-410 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Pvx-410
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating pvx-410 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
xbp1-us/xbp1-sp/cd138/cs1 multipeptide vaccine pvx-410, xbp1-us/xbp1-sp/cd138/cs1 multipeptide vaccine pvx-410
NCIT ID [1]:
C103823

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.